肿瘤药物治疗引发的心功能不全的心脏评估

赖玮; 帅维; 洪葵

doi:10.13201/j.issn.1001-1439.2016.03.003

肿瘤药物治疗引发的心功能不全的心脏评估

- 1 南昌大学第二附属医院心内科(南昌, 330006);
- 2 江西省分子医学重点实验室
基金项目:
教育部创新团队基金(No:IRT1141)

详细信息

通讯作者: 洪葵,E-mail:hongkui88@163.com

中图分类号: R541.9

收稿日期: 2015-05-23

Cardiac assessment of cancer drug therapy-induced cardiac dysfunction

- 1 Department of Cardiology, The Second Affiliated Hospital to Nanchang University, Nanchang, 330006, China;
- 2 Key Laboratory of Molecular Medicine of Jiangxi Province

More Information

Corresponding author: HONG Kui, E-mail: hongkui88@163.com

Received Date: 23 May 2015

摘要

摘要: 近年来肿瘤和心血管疾病的发病率呈显著上升趋势,肿瘤治疗中具有潜在心脏毒性的药物使用范围不断扩大,其导致的心功能不全等并发症也一直受到广泛关注。如何对化疗相关的心脏毒性进行早期诊断和治疗,并尽可能地降低心脏毒性损伤的程度,以最终改善患者预后已成为肿瘤医师和心血管医师共同关注的重要课题。本文主要根据2014美国UCG学会(ASE)和欧洲心血管成像协会(EACI)联合发表的共识声明,主要介绍多种影像学技术和生物学标志等方法对癌症患者进行心脏监测和评估,以降低癌症患者心血管并发症,并号召心内科医师与肿瘤科医师密切合作,早期诊断和预防性治疗可能是最理想的途径。
- 癌症治疗 /
- 心功能不全 /
- 影像学方法 /
- 生物学标志
Abstract: In recent years, the incidence of both cancer and cardiovascular disease has shown a significant upward trend. Furthermore, application of the anti antineoplastic drugs with cardiotoxicity is expanding. Therefore, more attention is being paid on antineoplastic drugcancer drug -induced heart dysfunction How to early diagnosis and treatment in chemotherapy-related cardiotoxicity and minimize the damage,has become an important issue for cardiologists and oncologists. According to the joint declaration issued by 2014 American Society of UCG (ASE) and the European Association of Cardiovascular Imaging (EACI), the article introduces a variety of imaging techniques and biomarkers methods, which are used to evaluate the heart function in patients underlying antineoplastic drug treatment. In this way the risk of cardiovascular complications should be reduced. The collaboration between cardiologists and oncologists should be enhancedd, which can facilitate early diagnosis and preventive treatment in chemotherapy-related cardiotoxicity.
- cancer treatment /
- heart failure /
- imaging methods /
- biological markers

HTML全文

参考文献(18)

[1]	TAN C,TASAKA H,YU K P,et al.Daunomycin,an antitumor antibiotic,in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemia[J].Cancer,1967,20:333-353.
[2]	KLEIN A L,ABBARA S,AGLER D A,et al.American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease:endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography[J].J Am Soc Echocardiogr,2013,26:965-1012.
[3]	LANCELLOTTI P,NKOMO V T,BADANO L P,et al.Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults:a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography[J].Eur Heart J Cardiovasc Imaging,2013,14:721-740.
[4]	ARMSTRONG G T,PLANA J C,ZHANG N,et al.Screening adult survivors of childhood cancer for cardiomyopathy:comparison of echocardiography and cardiac magnetic resonance imaging[J].J Clin Oncol,2012,30:2876-2884.
[5]	MOR-AVI V,LANG R M.Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy?[J].J Am Coll Cardiol,2013,61:85-87.
[6]	TAN-CHIU E,YOTHERS G,ROMOND E,et al.Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel,with or without trastuzumab as adjuvant therapy in node-positive,human epidermal growth factor receptor 2-overexpressing breast cancer:NSABP B-31[J].J Clin Oncol,2005,23:7811-7819.
[7]	PELLICORI P,CALICCHIA A,LOCOCO F,et al.Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol[J].Congest Heart Fail,2012,18:217-221.
[8]	SAWAYA H,SEBAG I A,PLANA J C,et al.Early detection and prediction of cardiotoxicity in chemotherapy-treated patients[J].Am J Cardiol,2011,107:1375-1380.
[9]	FALLAH-RAD N,WALKER J R,WASSEF A,et al.The utility of cardiac biomarkers,tissue velocity and strain imaging,and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy[J].J Am Coll Cardiol,2011,57:2263-2270.
[10]	THAVENDIRANATHAN P,POULIN F,LIM K D,et al.Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy:a systematic review[J].J Am Coll Cardiol,2014,63:2751-2768.
[11]	POTERUCHA J T,KUTTY S,LINDQUIST R K,et al.Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction[J].J Am Soc Echocardiogr,2012,25:733-740.
[12]	SAWAYA H,SEBAG I A,PLANA J C,et al.Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines,taxanes,and trastuzumab[J].Circ Cardiovasc Imaging,2012,5:596-603.
[13]	JIJI R S,KRAMER C M,SALERNO M.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs[J].J Nucl Cardiol,2012,19:377-388.
[14]	DOUGLAS P S,CARR J J,CERQUEIRA M D,et al.Developing an action plan for patient radiation safety in adult cardiovascular medicine:proceedings from the Duke University Clinical Research Institute/American College of Cardiology Foundation/American Heart Association Think Tank held on February 28,2011[J].J Am Coll Cardiol,2012,59:1833-1847.
[15]	GREENWOOD J P,MAREDIA N,YOUNGER J F,et al.Cardiovascular magnetic resonance and singlephoton emission computed tomography for diagnosis of coronary heart disease(CE-MARC):aprospective trial[J].Lancet,2012,379:453-460.
[16]	CARDINALE D,COLOMBO A,TORRISI R,et al.Trastuzumab-induced cardiotoxicity:clinical and prognostic implications of troponin I evaluation[J].J Clin Oncol,2010,28:3910-3916.
[17]	SCHMIDINGER M,ZIELINSKI C C,VOGL U M,et al.Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2008,26:5204-5212.
[18]	ROMANO S,FRATINI S,RICEVUTO E,et al.Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients[J].Br J Cancer,2011,105:1663-1668.